and commentary also appear in ACP Journal Club. Therapeutics EBM Volume 8 May/June 2003 83 www.evidence-basedmedicine.com group.bmj.com on August 27, 2017 Published by http://ebm.bmj.com/ Downloaded from

'UroLift' has emerged as a new minimally-invasive nonablative surgical technique for benign prostatic hyperplasia (BPH). We discuss the procedure, cost, evidence, advantages and disadvantages of this procedure. It is a novel technology suitable for a selected group of patients that allows for a bespoke treatment for men with BPH.

Symptomatic benign prostatic hyperplasia (BPH) occurs in one third of men over the age of 65 years. With an increase in the ageing population of Hong Kong, the number of men suffering from BPH is expected to increase in the next decade. These men will live longer, enjoy a better quality of life, and receive more comprehensive medical care for the remainder of their active lives than the previou...

Our treatment strategies for benign prostatic hyperplasia (BPH) have changed, with new insights into the pathophysiology of the disease, new clinical trials, and surgical advances. We present an update on treatment options and a diagnostic and treatment algorithm for this condition.

BACKGROUND Whereas geographical variations in intervention rates are well recognized, little is known about their implications for patient selection. This study looks at how the relative probability of being treated in different regions within England vary with a person's need for treatment, and whether higher intervention rates are associated with a greater probability of treatment at all leve...

The total area of the acini and the luminal area was statistically significantly greater in BPH. In normal and hyperplastic prostates, respectively, the total mean ( SD ) area (mm 2 ) of the acini was 0.041 (0.007) and 0.056 (0.016), of the lumen was 0.016 (0.003) and 0.036 (0.013), and of the epithelium was 0.025 (0.004) and 0.019 (0.003) (all P < 0.001). There was no statistically significant...

The results of an investigation show that there is no statistically significant excess of blood group A in cases of carcinoma of the oesophagus or in cases of benign prostatic hyperplasia.